3-[(dimethylamino)methyl]-5-methylhexan-2-one

We are 3-[(dimethylamino)methyl]-5-methylhexan-2-one CAS:91342-74-4 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:3-[(dimethylamino)methyl]-5-methylhexan-2-one
CAS.NO:91342-74-4
Synonyms:3-[(dimethylamino)methyl]-5-methylhexan-2-one
3-[(Dimethylamino)methyl]-5-methyl-2-hexanone
3-(N,N-dimethylaminomethyl)-5-methyl-2-hexanone
3-dimethylaminomethyl-5-methyl-hexan-2-one
 
Physical and Chemical Properties:
Density 0.9±0.1 g/cm3
Boiling Point 219.5±23.0 °C at 760 mmHg
Molecular Formula C10H21NO
Molecular Weight 171.280
Flash Point 60.7±13.7 °C
Vapour Pressure 0.1±0.4 mmHg at 25°C
Index of Refraction 1.437
 
Specification:
Appearance:Colorless transparent liquid
Assay:≥97.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Tetrabenazine(CAS:58-46-8).

3-[(dimethylamino)methyl]-5-methylhexan-2-one


Related News: An effective treatment for Alzheimer’s, which is estimated in 60%-70% of around 50 million dementia cases worldwide, could become one of the best-selling drugs globally.4-Bromo-4'-iodo-1,1'-biphenyl Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).22353-41-9 Onconova is currently in the clinical development stage with oral and IV rigosertib, including clinical trials studying single agent IV rigosertib in second-line higher-risk MDS patients (pivotal Phase 3 INSPIRE trial) and oral rigosertib plus azacitidine in first-line and refractory higher-risk MDS patients (Phase 2).3-Bromophenylboronic acid CAS:89598-96-9 The drug review center will establish a registration platform and database for APIs, pharmaceutical excipients and pharmaceutical packaging materials, which means that the domestic drug substance DMF system is expected to be gradually implemented.Active pharmaceutical ingredients directly impact disease.

Related Products
Product Name
2-Chloro-4-bromobenzaldehyde View Details
7-(3-Chloropropoxy)-6-methoxy-4-oxo-1,4-dihydro-3-quinolinecarbon itrile View Details
5-fluorocytidine View Details
2-Hydroxy-3-methoxy-3,3-diphenylpropanoic acid manufacturer 3,5-Dimethylpiperidine manufacturer 2-Methoxy-3-isobutyl pyrazine manufacturer 2-[4-(Dibutylamino)-2-Hydroxybenzoyl]Benzoic Acid manufacturer 2′-bromo-2-iodobiphenyl manufacturer